Imvax Inc.

Abcuro Inc.’s venture capital investors showed confidence in the ongoing Phase II/III MUSCLE clinical trial of ulviprubart (ABC008) in inclusion body myositis (IBM) by putting their support behind a $

Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago a

Relay Therapeutics, Inc. had the third-largest biopharmaceutical initial public offering in the US in 2020 when it sold 20 million shares at $20 each to gross $400m. It was the first of four IPOs by